Cardiovascular Phase 1 Deal Benchmarks — Ex-US (2026)

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $274M to $724M, with a median of $499M. Royalty rates for cardiovascular assets at this stage typically fall between 5.2% and 10.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.